Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03085849
Title SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Catherine Shu
Indications

lung small cell carcinoma

Therapies

Durvalumab + Guadecitabine + Tremelimumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.